|
Outcome variables
|
MHT users
|
Non-users
|
HR
|
95% CI
|
P
|
|---|
|
n
|
Rateb
|
n
|
Rateb
|
|---|
|
Any cancer
|
838
|
0.60
|
3918
|
0.57
|
1.053
|
0.977, 1.134
|
0.1800
|
|
GI cancer
|
182
|
0.13
|
1108
|
0.16
|
0.809
|
0.691, 0.946
|
0.0081
|
|
Gastric
|
65
|
0.05
|
403
|
0.06
|
0.787
|
0.605, 1.023
|
0.0733
|
|
Colorectal
|
60
|
0.04
|
388
|
0.06
|
0.757
|
0.577, 0.995
|
0.0457
|
|
Hepatobiliary
|
40
|
0.03
|
237
|
0.03
|
0.847
|
0.606, 1.186
|
0.3336
|
|
Pancreatic
|
16
|
0.01
|
68
|
0.01
|
1.163
|
0.674, 2.008
|
0.5872
|
- Other covariates (age group, income, region, Charlson comorbidity index, and year of study entry) were adjusted in each survival analysis
- CI confidence interval, GI gastrointestinal, HR hazard ratio, MHT menopausal hormone therapy
- aAdjusted hazard ratios for mortality in MHT users compared to non-users
- bThe incidence rates were calculated per 100,000 person-years
